Valeant Pharmaceuticals was upgraded to buy from hold by TheStreet Ratings on Tuesday. TheStreet Ratings gives Valeant Pharmaceuticals a B grade and $84.55 price target. The stock closed Thursday at $54.76 and has risen 17.28% year to date.
U.S. stock futures trade flat following another record close for the Dow; Amazon reportedly envisions opening 2,000 brick-and-mortar grocery stores; Apple Watch sales set a record, Apple CEO says.
European markets are set for a positive open Tuesday after Asia traders booked their best single-day gains in two weeks.
Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.
Stocks enjoyed another strong day on Wall Street as the financial sector pushed the S&P 500 higher.